EXOZYMES INC.
EXOZCIK 0002010788 · Biological Products, (No Diagnostic Substances) · Nasdaq
- Invizyne Technologies Inc (until 2025-01-21)
Revenue (TTM)
$70.07K
Q1 May 2026
Net Income (TTM)
−$8.87M
−56.3% YoY
Q1 May 2026
EPS Diluted (TTM)
−$1.05
−22.5% YoY
Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
-13,426.7%
Q1 May 2026
Net Margin
-12,664.6%
Q1 May 2026
Free Cash Flow (TTM)
−$6.67M
Q1 May 2026
Cash
$1.44M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
8.48M sh
Q1 May 2026
Revenue & Net Income
EPS (Diluted)
Margins
Cash Flow
Revenue Growth (YoY)
No data available for this metric.
Balance Sheet
Cash vs Debt
Latest news
All news →-
High Neutral
eXoZymes (EXOZ) Closes $6M Public Stock Offering
The biotech sold 330,575 units of common stock and warrants at $8.99 per share, raising roughly $5.95 million before fees.